NCT03723798View on ClinicalTrials.gov

Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome.

PHASE2CompletedINTERVENTIONAL

Enrollment

172

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

October 1, 2018

Study Completion Date

October 8, 2018

Conditions

Dry Eye Syndrome

Interventions

DRUG

SA001 Low dose

3 tablets b.i.d for 12 weeks

DRUG

SA001 Mid dose

3 tablets b.i.d for 12 weeks

DRUG

SA001 High dose

3 tablets b.i.d for 12 weeks

DRUG

Placebo

3 tablets b.i.d for 12 weeks

Trial Locations (1)

Unknown

Seoul St. Mary's Hospital, Seoul

All Listed Sponsors

lead

Samjin Pharmaceutical Co., Ltd.

INDUSTRY

NCT03723798 - Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome. | Biotech Hunter | Biotech Hunter